MiniMed expands Abbott partnership to develop dual glucose-ketone sensors for smart dosing systems

MiniMed Group
Medtronic

MiniMed Group

MMED

0.00

Medtronic

MDT

0.00
  • MiniMed expanded its agreement with Abbott to commercialize integrated dual glucose-ketone sensors for exclusive use with MiniMed smart dosing systems.
  • Product aims to add continuous ketone data to MiniMed’s dosing algorithm, supporting earlier alerts to reduce diabetic ketoacidosis risk.
  • Abbott’s dual glucose-ketone system has CE Mark, remains under FDA review, is not cleared or sold in the US.
  • Companies expect regulatory and commercialization milestone updates in coming months.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MiniMed Group Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606030647PR_NEWS_USPR_____LA74776) on June 03, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.